MERIDIAN, Idaho, Oct. 25 /– RxElite Holdings, Inc., a wholly-owned operating subsidiary of Southridge Technology Group, Inc. and a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that it will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York on November 5-7, 2007.
Jonathan Houssian, Chief Executive Officer and Founder of RxElite, will present on November 7 at 2:20 P.M. Eastern. Mr. Houssian will speak on the Company’s growth strategy as a specialty generic pharmaceutical company. For those unable to attend the event, the RxElite presentation is being webcast and can be accessed live or in replay format for a limited time at the following link: http://www.wsw.com/webcast/rrshq12/sout.ob
Presentations by more than 350 emerging growth biotechnology companies are expected at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference that rapidly has become the premier event on the Life Sciences calendar. Companies will share their accomplishments on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases, and medical device technology. The event will unite companies with institutional investors, venture capitalists, senior corporate executives, and experts from the scientific and medical communities. The Conference will include company presentations, breakout sessions, and one-on-one meetings with presenting companies.
About Rodman & Renshaw:
Rodman & Renshaw is a full service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies, along with research and sales and trading services to institutional investor clients that focus on such companies. Through its Acumen BioFin(TM) division, Rodman is a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
About RxElite Holdings, Inc.
RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Contact:
Corporate Information
Ph: (208) 288-5550
Toll Free: (800) 414-1901
Fax: (208) 288-1191
Investor Relations
Charlie Forshee, 215-885-4981
investorrelations@rxelite.com
Segue Ventures LLC
Source: RxElite Holdings, Inc.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated $18,000 directly from the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk
